Sugi Predict

Sugi Predict / Compounds / SCHEMBL6917550

SCHEMBL6917550

SCHEMBL6917550

CNc1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.65
▸ MAPT P10636 4/20 0.64
▸ LMNA P02545 3/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ TSHR P16473 1/20 0.61
▸ GPR119 Q8TDV5 7/20 0.60
▸ CYP2C19 P33261 1/20 0.56
▸ HTT P42858 2/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ JAK2 O60674 1/20 0.53
▸ JAK3 P52333 1/20 0.53
▸ ESR2 Q92731 1/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ NR2F2 P24468 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5573222 0.89 MAPT (0.76) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL19145920 0.89 NAMPT (0.65) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL15827727 0.89 NAMPT (0.52) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL21965381 0.87 NAMPT (0.63) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL13853617 0.87 NAMPT (0.66) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL3256196 0.86 NAMPT (0.69) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL29037711 0.86 NAMPT (0.69) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL24205419 0.85 NAMPT (0.61) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL24590338 0.85 NAMPT (0.61) NAMPTMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL31034622 0.85 NAMPT (0.67) NAMPTMAPTLMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561999-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY Abbvie Operations Singapore Pte. Ltd. (SG) 2025-06-04 — — EP disclosed
US-20240101540-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY ABBVIE BIOTECHNOLOGY LTD (BM) 2024-03-28 — — US disclosed
WO-2024026081-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY RIBON THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
WO-2023287736-A1 NOVEL BIS-AMIDE CONTAINING COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2023-01-19 — — WO disclosed
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-06-30 — — US disclosed
US-20220009933-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-13 — — US disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 — — US disclosed
EP-3187490-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-07-05 — — EP disclosed
US-9452980-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2016-09-27 — — US disclosed
US-9452980-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2016-09-27 — — US disclosed
US-20160264596-A1 SUBSTITUTED BENZAMIDES HOFFMANN-LA ROCHE INC. 2016-09-15 — — US disclosed
US-20160264596-A1 SUBSTITUTED BENZAMIDES HOFFMANN-LA ROCHE INC. 2016-09-15 — — US disclosed
WO-2013043232-A2 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER AFRAXIS, INC. (US) 2013-03-28 — — WO disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264596-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R NAMPT 1606/4885MAPT 387/4885LMNA 3001/4885
US-20210061760-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R NAMPT 1606/4885MAPT 387/4885LMNA 3001/4885
US-20110152245-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R NAMPT 1606/4885MAPT 387/4885LMNA 3001/4885
US-20220009933-A1 NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR IRAK4, IRAK1, IRAK2 NAMPT 2584/4885MAPT 2268/4885LMNA 1782/4885
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME TPX2, AIMP2, CDYL2 NAMPT 669/4885MAPT 4461/4885LMNA 3414/4885
US-20240101540-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY PARP14, PARP15, PARP16 NAMPT 574/4885MAPT 2494/4885LMNA 1912/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R NAMPT 1606/4885MAPT 387/4885LMNA 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.